For more information about healthcare performance, visit Abbott Diagnostics.
Chronic kidney disease (CKD) is a significant and growing clinical problem. Thus, accurate kidney function testing is important for monitoring of disease progression and for determining drug dosing given that many drugs are cleared by the kidneys. Estimated glomerular filtration rate (eGFR) is a critical parameter for understanding kidney function. However current methods for estimating GFR (Cockcroft–Gault, MDRD, and CKDEPI) are prone to significant bias in certain patients. This inaccuracy in eGFR can lead to incorrect drug dosing, increased complications, poor outcomes and increased costs.
This webinar highlights how an integrated clinical team from the Marienhospital, Stuttgart, sought to improve outcomes by reducing bias through implementation of parallel reporting of creatinine and of cystatin C-based eGFR calculations to identify patients with high risk for incorrect dosing of drugs cleared by the kidney. This collaboration had a measurable impact by enabling numerous chemotherapy dosing adjustments, increasing clinician confidence, optimizing hospital resources, and finally reducing costs of care.
What you will learn
- The current gaps and opportunities for improving kidney function testing
- How a multidisciplinary team implemented a best practice that involved parallel reporting of Creatinine and Cystatin C based eGFR to help identify patients at risk for incorrect drug dosing
- The impact that integrated clinical care teams can have on patient wellness and safety, clinician confidence, resource allocation, and cost optimization
Matthias Orth, MD PhD
Institute of Laboratory Medicine at the Marienhospital